1513. Absorption, Distribution, and Excretion of 14C‑APX001 after Single-Dose Administration to Rats and Monkeys
Session: Poster Abstract Session: Preclinical Study with New Antibiotics and Antifungals
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • 1513_IDWPOSTER - upload.pdf (308.0 kB)
  • Background:

    APX001 is a small-molecule therapeutic agent in clinical development for the treatment of invasive fungal infections (IFI). 

    Methods:

    The absorption, distribution and excretion profiles of [14C]APX001-derived radioactivity were determined in rats (albino and pigmented) and monkeys. Rats (some implanted with bile duct cannulae) were administered a single 100 mg/kg oral dose or a 30 mg/kg intravenous (IV) dose. Monkeys were administered a single 6 mg/kg IV dose. Samples of blood, urine, feces and bile, as well as carcasses, were collected through 168 hours after dosing. Samples were analyzed for total radioactivity content by liquid scintillation counting, and carcasses were analyzed by quantitative whole-body autoradiography.

    Results:

     [14C]APX001-derived radioactivity was rapidly and extensively absorbed and extensively distributed to most tissues for both routes of administration in both species. In rats, tissues with the highest radioactivity Cmax values included bile, abdominal fat, reproductive fat, subcutaneous fat, and liver, but radioactivity was also detected in tissues associated with IFI, including lung, brain and eye. In monkeys, the highest Cmax values were in bile, urine, uveal tract, bone marrow, abdominal fat, liver, and kidney cortex. Liver and kidney were the tissues with highest radioactivity, but as in the rat, radioactivity was also detected in lung, brain and eye tissues. In pigmented rats, radiocarbon was densely distributed into pigmented tissue and more slowly cleared than from other tissues.

    Mean recovery of radioactivity in rats was approximately 95-100%. In bile duct-intact rats, >90% of radioactivity was recovered in feces. In cannulated rats, biliary excretion of radioactivity was the major route of elimination and accounted for 88.8% of the dose, whereas urinary and fecal excretion of radioactivity was minor and accounted for 2.56% and 5.42% of the dose, respectively. In monkeys, the overall recovery of radioactivity was 87.6%, and was eliminated in feces (49.8% of dose) and to a lesser extent in urine (20.6% of dose).

    Conclusion:

    Together, the results indicate that APX001-related radioactivity is extensively distributed to major tissues (including tissues relevant to IFI) in both rats and monkeys and cleared primarily by biliary/fecal excretion.

    Robert Mansbach, PhD1, Karen J. Shaw, PhD1, Michael R. Hodges, MBBS, BSc2, Samantha Coleman, PhD3 and Michael E. Fitzsimmons, PhD3, (1)Amplyx Pharmaceuticals Inc., San Diego, CA, (2)Amplyx Pharmaceuticals, Inc., San Diego, CA, (3)Covance Laboratories, Madison, WI

    Disclosures:

    R. Mansbach, Amplyx Pharmaceuticals Inc.: Consultant , Consulting fee

    K. J. Shaw, Amplyx Pharmaceuticals Inc.: Employee , Salary

    M. R. Hodges, Amplyx Pharmaceuticals: Employee , Salary

    S. Coleman, Covance Laboratories: Employee , Salary

    M. E. Fitzsimmons, Covance Laboratories: Employee , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.